Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Bone Biologics (BBLGW) EPS (Weighted Average and Diluted) (2016 - 2017)

Bone Biologics (BBLGW) has disclosed EPS (Weighted Average and Diluted) for 2 consecutive years, with $0.25 as the latest value for Q2 2017.

  • Quarterly EPS (Weighted Average and Diluted) rose 292.31% to $0.25 in Q2 2017 from the year-ago period, while the trailing twelve-month figure was -$2.66 through Jun 2017, changed N/A year-over-year, with the annual reading at -$2.65 for FY2025, 90.85% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q2 2017 was $0.25 at Bone Biologics, up from -$0.13 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $0.25 in Q2 2017, with the low at -$0.13 in Q2 2016.